Get the Stockscreener App
8.95
3.14%
-0.29
After Hours:
8.96
0.01
+0.11%
Niagen Bioscience Inc stock is traded at $8.95, with a volume of 1.32M.
It is down -3.14% in the last 24 hours and up +48.18% over the past month.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
See More
Previous Close:
$9.24
Open:
$9.22
24h Volume:
1.32M
Relative Volume:
3.22
Market Cap:
$622.00M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+11.87%
1M Performance:
+48.18%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$8.72
$9.31
1-Week Range:
$8.01
$9.50
52-Week Range:
$5.33
$9.50
Niagen Bioscience Inc Stock (NAGE) Company Profile
Name
Niagen Bioscience Inc
Sector
Industry
Phone
310-388-6706
Address
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
8.95 | 622.00M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Oct-16-19 | Initiated | Oppenheimer | Outperform |
| Feb-14-19 | Initiated | B. Riley FBR | Buy |
| Nov-27-17 | Resumed | H.C. Wainwright | Buy |
| Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Niagen Bioscience Inc Stock (NAGE) Latest News
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st
Ratios Uncovered: Breaking Down Niagen Bioscience Inc (NAGE)’s Trailing Twelve Months Metrics - DWinneX
Niagen Bioscience: Q1 Earnings Snapshot - New Haven Register
Niagen Bioscience Inc (NAGE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook - BioSpace
Earnings call transcript: Niagen Bioscience Q1 2025 sales surge, stock rises - Investing.com
Niagen Bioscience Inc (NAGE) Q1 2025 Earnings: EPS of $0.07 Beats Estimate, Revenue Surges to $30.5 Million - GuruFocus
Niagen Bioscience (NAGE) Reports Record Q1 Revenue with Strong G - GuruFocus
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Niagen Bioscience Q1 2025 slides: revenue jumps 38%, raises full-year outlook - Investing.com
Niagen Bioscience, Inc. SEC 10-Q Report - TradingView
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 | NAGE Stock News - GuruFocus
Niagen Bioscience Reports Strong Q1 2025 Growth - TipRanks
What's Next: Niagen Bioscience's Earnings Preview - Nasdaq
Niagen Bioscience (NAGE) Expands Clinical Network with New Clinics - GuruFocus
Niagen IV therapy expands to nearly 600 clinics nationwide By Investing.com - Investing.com India
Niagen IV therapy expands to nearly 600 clinics nationwide - Investing.com
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide | NAGE Stock News - GuruFocus
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide - Nasdaq
Niagen Bioscience adds aging expert to advisory board By Investing.com - Investing.com India
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board | NAGE Stock News - GuruFocus
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advis - GuruFocus
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board - itemonline.com
Niagen Bioscience adds aging expert to advisory board - Investing.com
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 - Bluefield Daily Telegraph
Is Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Niagen Bioscience Inc [NAGE] stock for 2,146 USD was acquired by Lopez Carlos Luis - knoxdaily.com
Is it possible to buy Niagen Bioscience Inc(NAGE) shares at a good price now? - uspostnews.com
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) market cap up US$51m last week, benefiting both individual investors who own 36% as well as insiders - Yahoo Finance
Supplement Maker Rebrands - Los Angeles Business Journal
Robert Fried Exercises Options, Realizes $173KNiagen Bioscience (NASDAQ:NAGE) - Benzinga
Market Resilience: Niagen Bioscience Inc (NAGE) Finishes Weak at 5.42, Down -3.56 - DWinneX
Niagen Bioscience Confirms Its Operations Remain Unaffected By New Tariffs - marketscreener.com
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs - Business Wire
Niagen Bioscience maintains stability amid tariffs By Investing.com - Investing.com South Africa
Niagen Bioscience Stands Firm Despite Global Tariff Concerns - Finimize
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments - MarketScreener
Niagen Bioscience maintains stability amid tariffs - Investing.com
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) 30% Cheaper Price Remains In Tune With Revenues - simplywall.st
ChromaDex: Q4 Earnings Snapshot - marketscreener.com
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® - MarketScreener
H.C. Wainwright holds $11 target on Niagen Bioscience stock By Investing.com - Investing.com Canada
H.C. Wainwright holds $11 target on Niagen Bioscience stock - Investing.com
A Look At The Fair Value Of Niagen Bioscience, Inc. (NASDAQ:NAGE) - simplywall.st
Niagen Bioscience Stock Price, Quotes and Forecasts - Benzinga
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) - MarketScreener
Niagen Bioscience Inc Stock (NAGE) Financials Data
There is no financial data for Niagen Bioscience Inc (NAGE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):